Wide Ranks

ABSI

Absci Corporation

2.94

Top Statistics
Market Cap 337 M Forward PE -4.03 Revenue Growth 128.60 %
Current Ratio 5.63 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.48 Enterprise / Revenue 52.91 Price To Sales Trailing12 Months 80.27
Profitability
Profit Margins 0.00 % Operating Margins -1698.71 %
Balance Sheet
Total Cash 127 M Total Cash Per Share 1.11 Total Debt 11 M
Total Debt To Equity 5.96 Current Ratio 5.63 Book Value Per Share 1.76
All Measures
Short Ratio 982.00 % Message Board Id finmb_266013918 Shares Short Prior Month 13 M
Return On Equity -0.4911 City Vancouver Uuid cfcaddfc-dbcf-384a-9b76-cf40fa9f292c
Previous Close 2.75 First Trade Date Epoch Utc 1 B Book Value 1.76
Beta 2.19 Total Debt 11 M Volume 870091
Price To Book 1.67 Fifty Two Week Low 1.57 Total Cash Per Share 1.11
Total Revenue 4 M Shares Short Previous Month Date 1 B Target Median Price 7.00
Audit Risk 2 Max Age 86400 Recommendation Mean 1.62
Sand P52 Week Change 0.3133 Operating Margins -1698.71 % Target Mean Price 8.29
Net Income To Common -97668000 Short Percent Of Float 0.1540 Implied Shares Outstanding 114 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 127 M Next Fiscal Year End 1 B
Revenue Per Share 0.0400 Held Percent Insiders 0.2009 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 7
Regular Market Previous Close 2.75 Target Low Price 6.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.75 Open 2.81 Free Cashflow -36257124
State WA Dividend Yield 0.00 % Return On Assets -0.2740
Time Zone Short Name EST Board Risk 7 Trailing Eps -0.9300
Day Low 2.81 Address1 18105 SE Mill Plain Boulevard Shares Outstanding 114 M
Compensation Risk 9 Price Hint 4 Target High Price 13.00
Website https://www.absci.com 52 Week Change 0.7605 Average Volume 1 M
Forward Eps -0.7100 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 481.70 % Is_sp_500 False Regular Market Day High 3.02
Profit Margins 0.00 % Debt To Equity 5.96 Fifty Two Week High 6.72
Day High 3.02 Shares Short 12 M Regular Market Open 2.81
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 52.91
Revenue Growth 128.60 % Shares Percent Shares Out 0.1045 Operating Cashflow -70360000
Currency USD Time Zone Full Name America/New_York Market Cap 337 M
Is_nasdaq_100 False Zip 98683 Quote Type EQUITY
Industry Biotechnology Long Name Absci Corporation Overall Risk 7
Regular Market Day Low 2.81 Held Percent Institutions 0.6256 Current Price 2.94
Enterprise To Ebitda -2.48 Financial Currency USD Current Ratio 5.63
Industry Disp Biotechnology Number Of Analyst Opinions 7 Country United States
Float Shares 85 M Two Hundred Day Average 4.29 Governance Epoch Date 1 B
Enterprise Value 222 M Price To Sales Trailing12 Months 80.27 Forward PE -4.03
Regular Market Volume 870091 Ebitda -89714000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.

The company combines AI with scalable wet lab technologies to create biologics for patients.

Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.

It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI.

The company was founded in 2011 and is headquartered in Vancouver, Washington.